Metformin inhibits proliferation and promotes apoptosis of HER2 positive breast cancer cells by downregulating HSP90

被引:1
|
作者
Chen Tian-wen [1 ]
Liang Ya-nan [1 ]
Feng Duo [1 ]
Tao Lin-yu [1 ]
Qi Ke [1 ]
Zhang Hao-yun [1 ]
Wang Hong-xian [1 ]
Lin Qiu-sheng [1 ]
Kong Heng [1 ]
机构
[1] Guangdong Med Coll, Affiliated Nanshan Hosp, Dept Thyroid & Breast Surg, Shenzhen 518052, Peoples R China
来源
JOURNAL OF BUON | 2013年 / 18卷 / 01期
关键词
breast cancer; heat-shock protein90; HER2/neu; metformin; CHEMOTHERAPY; TRASTUZUMAB;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the effects and the possible molecular mechanisms of metformin on HER2 positive breast cancer cells. Methods: SK-BR-3 HER2 positive breast cancer cells were treated with different concentrations of metformin. The growth inhibitory rate of the cells was calculated by MTT assay, apoptosis was detected by flow cytometry, and the expression level of heat shock protein 90 (HSP90) was performed by Western blot analysis. A control group consisted of cells treated with PBS. Results: With increased concentrations of metformin, cell growth inhibitory rates increased. The growth inhibitory rates with 0.5 mM, 2mM or 8mM metformin were significantly higher compared with the control group (p<0.05). Apoptosis in the metformin treated cells was also significantly higher compared with the control group (p=0.003). The expression level of HSP90 in the metformin group was significantly lower than that in the control group. Conclusion: Metformin can inhibit the proliferation and promote apoptosis of HER2 positive breast cancer cells,which is maybe related to inhibition of HSP90.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 50 条
  • [41] FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation
    Huang, Wei
    Ye, Min
    Zhang, Lian-ru
    Wu, Qun-dan
    Zhang, Min
    Xu, Jian-hua
    Zheng, Wei
    MOLECULAR CANCER, 2014, 13
  • [42] The activity of prospective HSP90 inhibitors in breast cancer cells
    Khamidullina, A.
    Yastrebova, M.
    Tatarskiy, V.
    Khlebnicova, T.
    Scherbakov, A.
    Piven, Y.
    FEBS OPEN BIO, 2021, 11 : 315 - 315
  • [43] Why Is This Effective HSP90 Inhibitor Not Being Developed in HER2+ Breast Cancer?
    Arteaga, Carlos L.
    CLINICAL CANCER RESEARCH, 2011, 17 (15) : 4919 - 4921
  • [44] Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer
    Nguyen, Cong-Truong
    La, Minh Thanh
    Ann, Jihyae
    Nam, Gibeom
    Park, Hyun-Ju
    Park, Jung Min
    Kim, Yoon-Jae
    Kim, Ji Young
    Seo, Jae Hong
    Lee, Jeewoo
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 45
  • [45] IMMUNOTHERAPY FOR HER2 POSITIVE BREAST CANCER
    Vaidya, T. R.
    Ait-Oudhia, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S20 - S20
  • [46] Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells
    Bulut, Gulcan
    Atmaca, Harika
    Karaca, Burcak
    FUTURE ONCOLOGY, 2020, 16 (03) : 4485 - 4495
  • [47] Her2 positive breast cancer: practices
    Campone, Mario
    Berton-Rigaud, Dominique
    Bourbouloux, Emmanuelle
    Sophie, Sadot
    Zanetti, Alain
    Frenel, Jean-Sebastien
    BULLETIN DU CANCER, 2011, 98 (02) : 154 - 163
  • [48] Metformin inhibits breast cancer cell proliferation by downregulating cyclin D1
    Zhuang, Yongxian
    Miskimins, W. K.
    CANCER RESEARCH, 2006, 66 (08)
  • [49] Targeting HSP90 Inhibits Proliferation and Induces Apoptosis Through AKT1/ERK Pathway in Lung Cancer
    Niu, Mengyuan
    Zhang, Bin
    Li, Li
    Su, Zhonglan
    Pu, Wenyuan
    Zhao, Chen
    Wei, Lulu
    Lian, Panpan
    Lu, Renwei
    Wang, Ranran
    Wazir, Junaid
    Gao, Qian
    Song, Shiyu
    Wang, Hongwei
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [50] Blockade of Her2 binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2
    Fu, Liwu
    Zheng, Lisheng
    Yan, Yan-yan
    CANCER RESEARCH, 2011, 71